ClinConnect ClinConnect Logo
Search / Trial NCT05950191

LLIN Evaluation in Uganda Project (LLINEUP3)

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jul 10, 2023

Trial Information

Current as of September 07, 2025

Recruiting

Keywords

Long Lasting Insecticidal Nets With Chlorfenapyr Pyrethroid Long Lasting Insecticidal Nets With With Pbo Pyrethroid

ClinConnect Summary

The LLIN Evaluation in Uganda Project (LLINEUP3) is a clinical trial aimed at studying the effectiveness of two types of long-lasting insecticidal nets (LLINs) in reducing malaria cases in Uganda. In 2023, the National Malaria Control Division plans to distribute these nets for free to all households across the country. The trial will compare two different LLINs: one treated with a combination of chlorfenapyr and pyrethroid, and the other with a pyrethroid and PBO. By tracking the number of malaria cases in areas where these nets are used, the study hopes to identify which type of net is more effective in preventing malaria, which is a serious disease spread by mosquitoes.

To be eligible for this study, households must have at least one adult aged 18 or older who usually lives there and agrees to participate. For the clinical survey, it’s important that the adult or a parent/guardian provides consent, and children over 8 years old can also give their permission. Participants can expect to be part of an important effort to find better tools for fighting malaria, and their involvement will help shape future health policies and programs in Uganda. This trial is significant because it will be the first to evaluate the new PermaNet Dual LLINs, which could become an important part of malaria prevention strategies.

Gender

ALL

Eligibility criteria

  • Household Survey
  • Inclusion Criteria:
  • 1. At least one adult aged 18 years or older present
  • 2. Adult is a usual resident who slept in the sampled household on the night before the survey
  • 3. Agreement of the adult resident to provide informed consent for the household and entomology survey
  • Exclusion Criteria:
  • 1. Dwelling destroyed or not found
  • 2. Household vacant
  • 3. No adult resident home on more than 3 occasions
  • Clinical Survey
  • Inclusion Criteria:
  • 1. Usual resident who was present in the sampled household on the night before the survey
  • 2. Agreement of adult or parent/guardian (of children) to provide informed consent
  • 3. Agreement of child aged 8 years or older to provide assent
  • Exclusion Criteria:
  • 1. Resident not home on day of survey

About University Of California, San Francisco

The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.

Locations

Kampala, , Uganda

Patients applied

0 patients applied

Trial Officials

Moses Kamya, MBChB, MMed, PhD

Principal Investigator

Makerere University; Infectious Diseases Research Collaboration

Grant Dorsey, MD, PhD

Principal Investigator

University of California, San Francisco

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported